Teva Pharmaceutical Industries (TEVA) EBIAT (2016 - 2026)

Teva Pharmaceutical Industries has disclosed EBIAT across 11 years of filings, most recently posting $369.0 million for Q1 2026.

• Quarterly EBIAT rose 72.43% year-over-year to $369.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 214.07% YoY) and the FY2025 annual result came in at $1.4 billion, up 171.98% from the prior year.
• EBIAT fell to $369.0 million in Q1 2026, from $480.0 million in the prior quarter.
• Over five years, EBIAT peaked at $480.0 million in Q4 2025 and troughed at -$1.3 billion in Q4 2022.
• A 5-year average of -$195.5 million and a median of -$253.0 million in 2023 frame the typical range for EBIAT.
• Annual changes were most pronounced in 2022 — EBIAT plunged 1336.36% — and 2025, when it surged 274.55%.
• Tracing TEVA's EBIAT over 5 years: stood at -$1.3 billion in 2022, then jumped by 134.58% to $461.0 million in 2023, then plunged by 159.65% to -$275.0 million in 2024, then jumped by 274.55% to $480.0 million in 2025, then retreated by 23.12% to $369.0 million in 2026.
• Business Quant data shows TEVA's EBIAT at $369.0 million in Q1 2026, $480.0 million in Q4 2025, and $433.0 million in Q3 2025.